NewAmsterdam Pharma Company N.V.
NAMS NL00150012L7
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Topper James N O |
23.70 USD |
660 Bought |
15,639 USD |
15/09/2025 | 15/09/2025 |
| Kooij Louise Frederika CCO |
25.31 USD |
53,104 Sold |
1,344,062 USD |
09/09/2025 | 09/09/2025 |
| Kooij Louise Frederika CCO |
26.11 USD |
96,896 Sold |
2,529,955 USD |
09/09/2025 | 09/09/2025 |
| Topper James N O |
24.99 USD |
1,260 Bought |
31,487 USD |
08/09/2025 | 08/09/2025 |
| Kooij Louise Frederika CCO |
25.09 USD |
18,073 Sold |
453,452 USD |
03/09/2025 | 03/09/2025 |
| Kooij Louise Frederika CCO |
24.86 USD |
8,269 Sold |
205,567 USD |
25/08/2025 | 25/08/2025 |
| Kastelein Johannes Jacob Pieter CSO |
25.49 USD |
7,658 Sold |
195,202 USD |
21/08/2025 | 22/08/2025 |
| Kastelein Johannes Jacob Pieter CSO |
25.08 USD |
42,342 Sold |
1,061,937 USD |
21/08/2025 | 22/08/2025 |
| Kastelein Johannes Jacob Pieter CSO |
24.29 USD |
50,000 Sold |
1,214,500 USD |
21/08/2025 | 21/08/2025 |
| Topper James N O |
23.98 USD |
471 Bought |
11,294 USD |
11/08/2025 | 11/08/2025 |